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Intravaginal culture (IVC), also called INVO (intravaginal culture of oocytes), is an assisted reproduction procedure where oocyte
fertilization and early embryo development are carried out within a gas permeable air-free plastic device, placed into the maternal
vaginal cavity for incubation. In the present study we assessed the outcome of the INVO procedure, using the recently designed
INVOcell device, in combination with a mild ovarian stimulation protocol. A total of 125 cycles were performed. On average 6.5
oocytes per cycle were retrieved, and a mean of 4.2 were placed per INVOcell device. The cleavage rate obtained after the INVO
culture was 63%. The procedure yielded 40%, 31.2%, and 24% of clinical pregnancy, live birth, and single live birth rates per cycle,
respectively. Our results suggest that the INVO procedure is an eﬀective alternative treatment option in assisted reproduction that
shows comparable results to those reported for existing IVF techniques.
1.Introduction
Conventional in vitro fertilization (IVF) is the original
technique of the so-called test-tube babies and currently
an established treatment for infertility. The fertilization
of the oocytes with the spermatozoa is performed in the
laboratory, by simulating the physiological conditions to
which the gametes are exposed in vivo. Intravaginal culture
(IVC), also called INVO (intravaginal culture of oocytes),
is a procedure developed by Ranoux et al., 1988, proposed
as a simpliﬁed alternative option to conventional IVF [1].
In the procedure oocyte fertilization and early embryo
development are carried out within a gas permeable (CO2
and O2) air-free plastic device, placed into the maternal
vaginal cavity for incubation [1, 2], thus replacing the
complex IVF laboratory [3]. Few years ago, INVOcell device
was specially designed to overcome the diﬃculties and
improve the results obtained with the early prototype device,
which explained the occurrence of a low diﬀusion of the
procedure for years. This new device has been ISO 10993
tested (and mouse embryos tested) to assess toxicity and
biocompatibility and has received the European Union CE
mark declaration of conformity [3], which is equivalent to
approval by the Food and Drug Administration (FDA) in the
U.S.
INVO procedure has been used worldwide and results
from cycles performed by infertility centers around the
world, in countries such as France, Germany, The Nether-
lands, England, USA, and Japan, have been published [1, 2,
4–12]. More recently our center has pioneered the use of
this procedure employing the INVOcell device within the
Latin-American region [13]a n dh a sb e e nl e a d e ri ni t sr e c e n t
introduction in countries such as Mexico, Guatemala, El Sal-
vador, Nicaragua, Dominican Republic, Panama, Venezuela,
Ecuador, Peru, Bolivia, and Brazil.
In this study, we employed the INVO procedure using
the INVOcell device [14], in combination with a mild
ovarian stimulation protocol, with the aim of evaluating its
usefulness as an alternative treatment option for infertile
couples, in terms of embryonary development, clinical
pregnancy, and live birth rates.
2.MaterialsandMethods
2.1. Setting and Design. The present study was carried
out at the Colombian Center for Fertility and Sterility2 The Scientiﬁc World Journal
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Figure 1: Component parts of the INVOcell device. (a) Inner chamber. (b) Outer rigid shell. (c) Assembled INVOcell device with its
retention system.
(CECOLFES), Bogota, Colombia. The center is certiﬁed
according to ISO 9001 version 2008, and the study was
approved by the institutional ethics committee, which
allowed retrospective review of the patients’ ﬁles.
2.2. Study Population. One hundred twenty (120) infertile
couples with over 2 years of infertility were admitted
upon giving them information and receiving their informed
consent for treatment using the INVO procedure. Exclusion
criteria included severe endometriosis, polycystic ovary
syndrome, egg donation, and severe male factor.
From June, 2009, through May, 2011, one hundred
twenty ﬁve (125) INVO cycles were performed. Population
was ranked by age among four diﬀerent groups to report
clinical pregnancy, live birth, and single live birth rates in
order to compare the outcome of the INVO procedure.
Patients were distributed in groups as follows: ≤29, between
30 and 34, between 35 and 39, and ≥40 years old.
2.3. Controlled Ovarian Stimulation. Mild ovarian stimula-
tion protocol was started with ovarian quiescence using oral
contraceptive pills containing 150μg of desogestrel and 30μg
of ethinylestradiol (Marvelon Schering Plough., Bogota,
Colombia) for 3 weeks. Clomiphene citrate (50 or 100mg;
Omiﬁn Cipla Ltd., Bernagoa, India) and human menopausal
gonadotropin (one or two ampoules of 75IU; Merional
IBSA, Switzerland) were administered starting on day three
of the following cycle until follicles reached 14–16mm in
diameter; at that point, blockage of follicular rupture to
prevent spontaneous ovulation was achieved by administra-
tion of Indomethacin (50mg; Genfar, Cali, Colombia) three
timesperdayuntiloocyteretrieval[15].Whenthedominant
follicle(s) reached 17-18mm in diameter human chorionic
gonadotropin (10,000IU; Gonacor Massone, Buenos Aires,
Argentina) was injected, and 36 hours later transvaginal
oocyte retrieval was performed under ultrasound guidance
by traditional techniques [16].
2.4. Oocytes Selection. The maturity of the oocytes was mor-
phologically assessed as traditionally, under stereo micro-
scope with 8x magniﬁcation, based upon the expansion and
radianceofthecumulus/coronaoocytecomplex(COC)[17],
using criteria such as cumulus viscosity and dissociation
of the cumulus corona radiate, additionally when possible
nuclear maturity was conﬁrmed by observation of the polar
body.
2.5. Intravaginal Culture Procedure. The INVOcell device
(INVO Bioscience., Beverly, MA, USA, http://www.invo-
bioscience.com/) is composed of an inner chamber with a
rotating valve and a protective outer rigid shell (Figure 1).
The INVO procedure was performed as previously described
with some modiﬁcations [3]. Semen samples were treated by
the swim-up method [18]. Initially the device inner chamber
is ﬁlled with pregazed and prewarmed G2 Plus version 5
medium (Vitrolife AB, Goteborg, Sweden), then a count
of 35.000–50.000 spermatozoa are loaded, followed by the
selected number of oocytes (4.2 in average). After assembly
of the device, it is immediately positioned into the vaginal
cavity, in proximity to the uterine cervix, altogether with
a diaphragm as retention system. Some recommendations
were given to patients to follow during the culture period
such as restraining from intercourse and abstention of tub
bathing, douching, or swimming.
After a 72-hour culture period the INVOcell device was
removed, embryos were retrieved and immediately evaluated
according to their development and fragmentation degree.
The selected embryos were transferred under transabdomi-
nal ultrasound guidance.
2.6. Luteal Phase Support and Pregnancy Determination.
Estradiol Valerianate (4mg; Delpharm Lille SAS, Paris,
France) and natural oily progesterone (100mg; Ryan Labo-
ratories, Bogota, Colombia) were given daily during 6 days
starting the day of transfer, followed by vaginal progesterone
(600mg/day; Utrogestan Besins International, Paris, France)The Scientiﬁc World Journal 3
Table 1: Summary of results from the INVO procedure.
Groupsa Cycles (n)T r a n s f e r s b (n)R e t r i e v a l c INVOcelld Cleavagee ETf Pregnancyg
≤29 17 16 (94,1) 7,53 4,59 2,7 (58,7) 2.3 10 (58,8)
30–34 54 51 (94,4) 6,52 3,8 2,8 (73,7) 2.3 22 (40,7)
35–39 48 43 (89,6) 6,23 4,27 2,5 (58,5) 2.0 17 (35,4)
≥40 6 4 (66,7) 5,5 5 1,5 (30) 1.5 1 (16,66)
Total 125 114 (91,2) 6,5 4,2 2,6 (63) 2,1 50 (40)
INVO: intravaginal culture of oocytes; ET: embryo transfer. Values in parentheses are percentages.
aRanges of ages. bC y c l e st h a te n d e du pi nt r a n s f e r .cMean number of retrieved oocytes per punction. dMean number of oocytes placed for fertilization per
INVOcell device (cycle). eMean number of retrieved viable proper developed embryos per INVOcell device (cycle). fMean number of transferred embryos per
cycle. gNumber of clinical pregnancies per cycle.
until day 12 after-transfer, when serum β-HCG pregnancy
determination was performed. Seven weeks after transfer,
the presence of gestational sac with fetal heart beat by
ultrasonography was used to conﬁrm the clinical pregnancy.
2.7. Vitriﬁcation. In some patients, supernumerary oocytes
conﬁrmed to be mature by ﬁrst polar body observation
after denudation, as well as those good quality embryos that
were not transferred, were vitriﬁed for use in subsequent
cycles. Vitriﬁcation was performed according to the protocol
previously published by our group [19].
2.8. Outcome Measures and Statistical Analysis. Primary
outcome measures included pregnancy, live birth, and single
live birth rates per transfer. Secondary outcome measures
included mean numbers of retrieved oocytes and oocytes
placed per INVO device, as well as embryo cleavage and
transfer rates after INVO culture. Statistical analysis, to com-
pareourresultswithpublisheddataconcerningconventional
IVF outcomes, was performed using Student’s t-test. P<
0.05 was considered statistically signiﬁcant.
3. Results
One hundred twenty-ﬁve (125) cycles combining the INVO
procedure and mild ovarian stimulation protocol were
performed. There was no cycle cancellation, as all started
cycles went to retrieval. A total of 812 oocytes were retrieved,
for an average of 6.5 per puncture. A mean of 4.2 oocytes
were placed for insemination per the INVO device. On
average 2.6 embryos per cycle were obtained, for a cleavage
rate of 63%, out of which a mean of 2.1 embryos were
transferred per cycle, for a total of 114 transfers (91.2%).
Cycle distribution per patient’s age groups was seventeen for
≤29, 54 for 30–34, 48 for 35–39, and 6 for ≥40 years old
(Table 1).
3.1. Patients ≤ 29 Years Old. A total of 128 oocytes were
retrieved (mean value 7.5), out of which 78 were selected
for insemination (average 4.6). After intravaginal culture, 46
embryos (on average 2.7 per cycle) were obtained, out of
which an average of 2.3 embryos per cycle were selected for
transference, and the remaining viable embryos were cry-
opreserved. Twelve positive β-HCG tests were obtained, out
of which 10 clinical pregnancies were conﬁrmed (Table 1).
Up to date 6 pregnancies have successfully reached live birth
with eight healthy children born, and there is one ongoing
pregnancy.
3.2. Patients between 30 and 34 Years Old. A total of 352
oocytes were retrieved (mean value 6.5), out of which
207 were selected for insemination (average 3.8). After
intravaginal culture, 152 embryos (on average 2.8 per cycle)
were obtained, out of which an average of 2.3 embryos per
cycle were selected for transference, and the remaining viable
embryos were cryopreserved. Twenty-six positive β-HCG
tests were obtained, out of which 22 clinical pregnancies
were conﬁrmed (Table 1). Up to date 12 pregnancies have
successfully reached live birth and 17 healthy children were
born, and there are 5 ongoing pregnancies.
3.3. Patients between 35 and 39 Years Old. A total of 229
oocytes were retrieved (mean value 6.2), out of which
205 were selected for insemination (average 4.3). After
intravaginal culture, 121 embryos (on average 2.5 per cycle)
were obtained, out of which an average of 2.0 embryos per
cycle were selected for transference, and the remaining viable
embryos were cryopreserved. Eighteen positive β-HCG tests
wereobtained,outofwhich17clinicalpregnancieswerecon-
ﬁrmed (Table 1). Up to date 12 pregnancies have successfully
reached live birth and 17 healthy children were born, and
there are 2 ongoing pregnancies.
3.4. Patients ≥ 40 Years Old. A total of 33 oocytes were
retrieved (mean value 5.5), out of which 30 were selected
for insemination (average 5.0). After intravaginal culture, 9
embryos (on average 1.5 per cycle) were obtained, out of
which an average of 1.5 embryos per cycle were selected for
transference, and the remaining viable embryos were cryop-
reserved. One clinical pregnancy was conﬁrmed (Table 1),
up to date this is a healthy ongoing pregnancy.
Out of the 125 cycles, 11 were not transferred and in
two of them there were well-developed embryos but transfer
could not be achieved, one because an abnormal uterine
bleeding and the other due to the presence of bicornuate
uterus in retroversion, in both cases embryos were vitriﬁed.
In the remaining 9 cycles there was either not fertilization
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Figure 2: Rates of primary outcomes: pregnancy, live birth,
and singleton live birth from INVO procedure. ∗From the US
Centers for Disease Control and Prevention (CDC), 2009 National
Summary Report. P>0.05 for pregnancy rates between traditional
IVF versus INVO (T-test). For INVO results, live birth and single
live birth rates include up to date ongoing pregnancies.
Noneofthe120patientsreportedanydiscomfortwhileusing
the INVOcell device or presented signs of infection.
4. Discussion
In the present study we assessed the outcome of the INVO
procedure, using the specially designed INVOcell device, in
terms of pregnancy, live birth, and single live birth rates; our
results showed comparable successful rates with traditional
IVF, highlighting its usefulness as an alternative option
treatment in assisted reproduction.
The US Centers for Disease Control and Prevention
(CDC) provides cumulative summary statistics on the
outcomes of IVF cycles; the most recent complete data
available are from 2008 [20]. During that year the pregnancy,
live birth, and singleton live birth rates per oocyte retrieval
were 41.6%, 33.8%, and 23%, respectively. These results
a r ec o m p a r a b l et oo u r sf r o mI N V Oc y c l e sa sw eo b t a i n e d
40%, 31.2%, and 24%, respectively, for these outcomes.
Patients’ age was the most predictive factor of success with
a marked decrease across the groups of age from ≤29 until
≥40 years old, in terms of pregnancy, live birth, and single
live birth rates (Figure 2). More recently available data report
a pregnancy rate per cycle of 55% for patients of 29 years
old and under, 47% for patients between 30 and 34, 34% for
patients between 35 and 39, and 17% for patients 40 years
old and older [21]. These results are also comparable to ours
for the INVO procedure, where as expected pregnancy rates
decreased with maternal age, from 58.8%, through 40.7%
and 35.4%, until 16.7%, for woman aged ≤ 30, 30–34, 34–
39, and ≥ 40 years old, respectively. There were no statistical
diﬀerences for pregnancy rate through age groups between
the reported data and our results (P = 0.96) (Figure 2).
Taken together, these results suggest that the INVO proce-
dure could be an alternative treatment for infertile patients
ensuring success rates comparable to those in the existing
IVF techniques.
Cycle secondary outcomes, including mean numbers of
retrieved oocytes and oocytes placed per INVO device, in
addition to embryos cleavage and transfer rates after INVO
culture, were comparable between the ﬁrst three established
groups of age. However, the last group of age (≥40 years old)
showed notably lower mean values within these measures
(Table 1).
The higher incidence of multiple pregnancies secondary
to IVF is well recognized. The 2008 CDC annual report
indicates a 55.5% of singleton and 26% of multiple live
births (20). In comparison, in our results the multiple
gestationratewas1.4timesless(18%)thanthereported.Our
pregnancies were distributed as follows: 60% single, 12%
twins, and 6% triple live births, as a result of transferring on
average 2.4 embryos per transferred cycle. The advances of
ART have involved among other things evolution of culture
media components; however, the environmental conditions
inﬂuence drastically the embryo quality by their eﬀect on
O2 and CO2 concentration, pH, and temperature [22–25]; a
misbalance in this components may induce oxidative stress,
responsible forinappropriate early development and embryo
fragmentation [26]. Oxygen is an important player during
embryo development [27]; the INVO procedure oﬀers an
in vivo fertilization environment with the eﬀectiveness of
an oxygen concentration that closely resembles the uterine
cavity atmosphere of less than 5% of oxygen. This concen-
tration of oxygen ensures the energetic metabolism required
for a successful gametes viability, activation, fertilization,
and embryo development, which takes place under near
anaerobic conditions [28]. On the other hand, CO2 is a
key atmospheric component during embryo development;
in the culture media it produces carbonic acid that is equi-
librated with sodium bicarbonate originating the optimal
pH necessary for embryo development [29]. In traditional
large gas-ﬁlled incubators, the CO2 concentrations may vary
because of repeated opening, impacting the pH equilibrium
in the culture medium, decreasing embryo quality [30]. In
contrast the INVOcell device is a closed system able to keep
temperature and pH stability during 72h of uninterrupted
embryo culture, providing a stable, pure, inexpensive, and
easy-access source of the required oxygen/CO2 concentra-
tion. A limitation of the intravaginal culture would be the
inability to monitor or adjust gas levels; however, according
to our results we could ensure that this system is capable
of maintaining an environmental stability that achieves
comparable results to those obtained with large gas-ﬁlled
incubators [29, 31]. In our study, from 520 oocytes loaded
into the INVOcell device, 326 viable embryos (with a proper
development of 6–8 cells after 72 hours of culture) were
retrieved; additionally 79.6% of these embryos were free
of fragmentation. These results suggest that the INVOcellThe Scientiﬁc World Journal 5
procedure oﬀers an appropriate embryo development with
an optimal quality for implantation success. Infertile couples
during assisted reproduction treatments undergo an intense
process that involves physiological diﬃculties, physical dis-
comfort, psychological and economical implications, in
addition to the medical procedures that represent risks and
secondary eﬀects [32, 33]. A signiﬁcant aspect of the INVO
procedure lies in the psychological beneﬁt that is created
amongthepatientswhofeelcloselyinvolvedintheprocessof
fertilization and early embryo development, what generates
a high level of acceptance of the procedure. The INVOcell
is placed into the vaginal cavity altogether with a retention
system (diaphragm) (Figure 1(c)) that situates it close to
the uterus, the holes in the diaphragm membrane avoid the
accumulation of vaginal secretions that would be responsible
for infection induction during intravaginal culture period.
Accordingly in our study no patient reported any infection
or physical discomfort while or after using the device.
An advantage of the INVO procedure is the fact that
by simplifying the laboratory equipment and manipulation
needed, it might decrease the costs and allow a widespread
application for patients who cannot aﬀord traditional IVF
[34], as it would be the case in developing countries, where
the access to cost-eﬀective infertility treatments is limited.
This study suggests that intravaginal culture using the
INVOcell device could be a viable alternative option for
assisted reproduction. However, additional prospective and
probably multicentric studies, involving higher number of
cycles, would be necessary to conﬁrm its eﬃcacy and
safety. Additionally it would be interesting to investigate
the outcome and usefulness of the INVO culture system
in conjunction with the ICSI technique, to evaluate its
applicability for indications such as severe male factor.
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